BioSpace News Archive

CartiHeal, developer of Agili-C™, a proprietary implant for the treatment of cartilage lesions in arthritic and non-arthritic joints, announced today that FDA has granted Breakthrough Device Designation for the Agili-C implant™. FDA’s Brea

Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of small molecule, tumor-agnostic therapies, today announced that pre-clinical data on the Company’s lead product candidate BDTX-189 will be presented at the 32 nd EORTC-NCI-AACR Virtual Symposium on Molecular Targets and Cancer Therapeutics (ENA 2020) taking place October 24-25, 2020. Presentation de

Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) will announce results for the second quarter ended September 30, 2020 on Wednesday, October 28th, 2020 after the Board Meeting.

Exact Sciences Corp. (NASDAQ: EXAS) today announced the introduction of the Oncotype MAP™ Pan-Cancer Tissue test for patients with advanced, metastatic, refractory, or recurrent cancer. The Oncotype

Solera Health, the premier platform for addressing chronic conditions, today announced Mary Langowski as its new Chief Executive Officer (CEO).

Zebra Technologies Corporation (NASDAQ: ZBRA), an innovator at the front line of business with solutions and partners that deliver a performance edge, today announced new healthcare solutions designed to enable positive patient identification, increase operational efficiencies, and deliver improved patient care.

Oct. 12, 2020 14:09 UTC CORRECTING and REPLACING PerkinElmer Updates Third Quarter Outlook; To Hold Earnings Call on Wednesday, October 28, 2020

Fund seeks applications from local non-profits in affected communities in Silicon Valley, South Bay and Detroit metro area

GEHA today announced that Mary Beth Vitale, Corporate Director, has been named one of the most influential leaders in the boardroom by the National Association of Corporate Directors (NACD) as part of their 2020 NACD Directorship 100™, an annual list of leading corporate directors and governance advocates.

OSE Immunotherapeutics (ISIN: FR0012127173; Mnemo: OSE) announced the European Patent Office’s (EPO) issuance of a notice of allowance for its Phase-2 ready product FR104, a first-in-class selective CD28-antagonist. Specifically, this European patent will provide additional protection covering novel dosing regimen of FR104 for the prevention and treatment of T-lymphocyte-mediated autoimmune diseases, inflammatory diseases, transplantation and